Clinical bottom line
Chronic pruritic lichen planopilaris (LPP) remains a challenging cicatricial alopecia with limited high-quality evidence guiding systemic treatment. Hydroxychloroquine is the most studied systemic agent, showing moderate efficacy and a generally favorable safety profile, supported by validated disease activity scoring systems (Harries et al., 2010; Glick et al., 2011). Emerging data suggest low-dose oral minoxidil may offer symptomatic improvement and hair regrowth in LPP, but evidence is preliminary and limited to small cohorts (Saber et al., 2025). Mycophenolate mofetil has also been used with some success in refractory cases, though robust controlled data are lacking (Michaels et al., 2011). Overall, systemic therapies warrant cautious use, tailored to disease severity and patient tolerance, with close monitoring for adverse effects.
What the evidence shows
Hydroxychloroquine has been the cornerstone systemic treatment for LPP, with studies demonstrating its ability to reduce inflammation and stabilize hair loss. Harries et al. (2010) introduced the Lichen Planopilaris Activity Index (LPPAI), a validated clinical scoring system that has facilitated objective assessment of treatment response. Their work and subsequent reports (Glick et al., 2011) indicate that hydroxychloroquine can achieve disease control in a substantial proportion of patients, though complete remission is uncommon. The drug’s immunomodulatory effects likely mitigate the T-cell mediated follicular destruction characteristic of LPP.
More recently, low-dose oral minoxidil has been explored as an adjunctive therapy. Saber et al. (2025) reported on its efficacy and safety in a cohort of LPP patients, noting improvements in pruritus and partial hair regrowth. While minoxidil’s vasodilatory and follicular stimulation properties are well established in androgenetic alopecia, its role in inflammatory cicatricial alopecias remains investigational and requires validation in larger, controlled studies.
Mycophenolate mofetil, an immunosuppressant, has been used off-label for refractory LPP. Michaels et al. (2011) described its use in patients unresponsive to first-line agents, with some achieving disease stabilization. However, data are limited to case series and retrospective analyses, and the risk-benefit profile must be carefully considered given potential systemic immunosuppression.
Caveats and uncertainty
The evidence base for systemic treatments in LPP is limited by small sample sizes, lack of randomized controlled trials, and heterogeneity in outcome measures. The LPPAI scoring system (Harries et al., 2010) represents progress toward standardized assessment but is not universally adopted. Long-term safety data for hydroxychloroquine in LPP are extrapolated from other indications, and monitoring for retinal toxicity remains essential.
The promising findings for low-dose oral minoxidil (Saber et al., 2025) are preliminary, with potential confounding by concomitant therapies and absence of placebo-controlled data. Similarly, mycophenolate mofetil use is based on limited observational evidence, and its immunosuppressive risks necessitate caution.
Differential diagnosis is critical, as conditions mimicking LPP, such as folliculitis decalvans, require distinct management strategies (Matard et al., 2020). Misclassification may confound treatment outcomes and safety assessments.
How this may change practice
Clinicians managing chronic pruritic LPP should consider hydroxychloroquine as a first-line systemic option, utilizing the LPPAI to monitor response objectively. Patient counseling should emphasize the need for regular ophthalmologic screening and realistic expectations regarding disease control rather than cure.
Low-dose oral minoxidil may be considered as an adjunct in select patients, particularly those with persistent pruritus or incomplete response to immunomodulatory therapy, but only with careful monitoring and recognition of its investigational status.
For refractory cases, mycophenolate mofetil could be an option after weighing risks and benefits, ideally in consultation with dermatology specialists experienced in immunosuppressive therapy.
Ongoing research and clinical trials are needed to establish standardized treatment algorithms and to validate emerging therapies. Meanwhile, a multidisciplinary approach including dermatologists, pathologists, and patient education remains essential for optimal management.